Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital of Guangzhou Medical University
About this trial
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Eligibility criteria
Qualifiers
Pathologically confirmed or clinically diagnosed HCC
Diagnosis of HCC with TACE refractoriness according to the criteria proposed by Japan Society of Hepatology (2021)
Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included
At least one measurable intrahepatic target lesion
Disqualifiers
Extrahepatic metastasis
Tumor thrombus involving main portal vein or both the first left and right branches of portal vein
Vena cava invasion
Patients who received prior hepatic arterial infusion chemotherapy (HAIC), radiotherapy, or systemic therapy, for HCC
Trial design
Treatments tested in this trial
- Lenvatinib plus SIRT
- Lenvatinib
Treatment groups
78 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov